Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
116 hot topic(s) found with the query "Hypertension"

RNA Injection Every 6 Months to Improve Adherence and Lower Blood Pressure in Patients With Hypertension.
Ernesto L Schiffrin et al. JAMA 2024 2 (Posted: Feb 18, 2024 7AM)

From the article: "A new report from the KARDIA-1 clinical trial demonstrates that reducing angiotensinogen with the silencing RNA zilebesiran, BP may be lowered with injections of the small interfering RNA every 6 months, which could prove useful for improving adherence to treatment. The use of an injection every 6 months, if shown to produce sustained BP lowering, could help achieve goal BP in patients who do not adhere to currently prescribed antihypertensive treatment, a major cause of both uncontrolled and difficult to control hypertension. "

Association Between a First-Degree Family History and Self-Reported Personal History of Obesity, Diabetes, and Heart and Blood Conditions: Results From the All of Us Research Program.
Danielle Rasooly et al. J Am Heart Assoc 2023 11 e030779 (Posted: Nov 13, 2023 8PM)

From the abstract: "We assessed the association between a self-reported family history of ODHBs and their risk in the adult population (age =20 years) of the AoU (All of Us) Research Program, a longitudinal cohort study of diverse participants across the United States. We conducted a family history-wide association study to systematically assess the association of a first-degree family history of 15 ODHBs in AoU. We use the FamWAS method to estimate 225 familial associations among 15 ODHBs. The results include overlapping associations between family history of different types of cardiometabolic conditions (such as type 2 diabetes and coronary artery disease), and their risk factors (obesity, hypertension), where adults with a family history of 1 ODHB exhibited 1.1 to 5.6 times (1.5, on average) the odds of having a different ODHB. "

Primary aldosteronism: molecular medicine meets public health.
Elena A B Azizan et al. Nat Rev Nephrol 2023 8 (Posted: Aug 25, 2023 8AM)

Cost effectiveness review of text messaging, smartphone application, and website interventions targeting T2DM or hypertension.
Ruben Willems et al. NPJ Digit Med 2023 8 (1) 150 (Posted: Aug 21, 2023 8AM)

Digital health interventions have been shown to be clinically-effective for type 2 diabetes mellitus (T2DM) and hypertension prevention and treatment. This study synthesizes and compares the cost-effectiveness of text-messaging, smartphone application, and websites. We found that digital interventions are cost-effective without substantial differences between the different delivery modes. Future health economic studies should increase transparency, conduct sufficient sensitivity analyses, and appraise the ICUR more critically in light of a reasoned willingness-to-pay threshold.

Silencing Angiotensinogen in Hypertension.
Rhian M Touyz et al. N Engl J Med 2023 7 (3) 278-281 (Posted: Jul 20, 2023 7AM)

Addressing the challenges to improve antihypertensive therapy together with the urgency for better blood-pressure control has led to renewed interest in the development of targeted, simplified approaches to treatment. For the first time in almost 20 years, numerous new drug classes have been tested in clinical trials. These drugs are typically targeted with greater precision than previous drugs, have fewer side effects, and are user-friendly and of durable effect.

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
Akshay S Desai et al. N Engl J Med 2023 7 (3) 228-238 (Posted: Jul 20, 2023 7AM)

Angiotensinogen is the sole precursor of angiotensin peptides and has a key role in the pathogenesis of hypertension. Zilebesiran, an investigational RNA interference therapeutic agent with a prolonged duration of action, inhibits hepatic angiotensinogen synthesis. Dose-dependent decreases in serum angiotensinogen levels and 24-hour ambulatory blood pressure were sustained for up to 24 weeks after a single subcutaneous dose of zilebesiran of 200 mg or more.

Cost-Effectiveness Analysis of Personalized Hypertension Prevention
ST Wang, J Per Med, June 15, 2023 (Posted: Jun 16, 2023 1PM)

While a population-wide strategy involving lifestyle changes and a high-risk strategy involving pharmacological interventions have been described, the recently proposed personalized medicine approach combining both strategies for the prevention of hypertension has increasingly gained attention. However, a cost-effectiveness analysis has been hardly addressed. The personalized preventive treatment appeared more cost-effective than population-based conventional care. These findings are extremely valuable for making hypertension-based health decisions based on precise preventive medication.

Polygenic prediction of preeclampsia and gestational hypertension.
Michael C Honigberg et al. Nat Med 2023 5 (Posted: May 30, 2023 6AM)

Here we tested the association of maternal DNA sequence variants with preeclampsia in 20,064 cases and 703,117 control individuals and with gestational hypertension in 11,027 cases and 412,788 control individuals across discovery and follow-up cohorts using multi-ancestry meta-analysis. Altogether, we identified 18 independent loci associated with preeclampsia/eclampsia and/or gestational hypertension, 12 of which are new (for example, MTHFR–CLCN6, WNT3A, NPR3, PGR and RGL3), including two loci (PLCE1 and FURIN) identified in the multitrait analysis.

A call to personalize anti-hypertensive treatments.
Karen O'Leary et al. Nat Med 2023 4 (Posted: May 03, 2023 6AM)

A randomized, controlled trial evaluated four classes of anti-hypertensive drugs and — crucially — incorporated a repeated-crossover design to control for background variation. They found substantial variation in response to different treatments and calculated that a personalized approach to treatment selection could lower blood pressure by an additional 4.4 mm Hg, on average. The data highlight the need for personalized approaches to hypertension treatment. The authors suggest that in the future, wearable devices could enable rapid evaluation of treatment effects and better personalization of anti-hypertensive therapy.

The role of aldehyde dehydrogenase 2 in cardiovascular disease.
Jian Zhang et al. Nature reviews. Cardiology 2023 2 (Posted: Feb 26, 2023 8AM)

Aldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme involved in the detoxification of alcohol-derived acetaldehyde and endogenous aldehydes. The inactivating ALDH2 rs671 polymorphism, present in up to 8% of the global population and in up to 50% of the East Asian population, is associated with increased risk of cardiovascular conditions such as coronary artery disease, alcohol-induced cardiac dysfunction, pulmonary arterial hypertension, heart failure and drug-induced cardiotoxicity.

Analysis of Pregnancy Complications and Epigenetic Gestational Age of Newborns
CL Acosta et al, JAMA Network Open, February 24, 2023 (Posted: Feb 24, 2023 11AM)

Is exposure to gestational diabetes, gestational hypertension, or preeclampsia associated with biological gestational age, measured via epigenetic clocks, in newborns? In this national multisite cohort study of 1801 children, preeclampsia and gestational diabetes were significantly associated with decelerated gestational age in exposed offspring at birth vs unexposed offspring (ie, they were estimated to be biologically younger than their chronological gestational age), and these associations were more pronounced in female offspring. No associations were observed for gestational hypertension and accelerated or decelerated biological age.

Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases.
Kiiskinen Tuomo et al. Nature medicine 2023 1 (Posted: Jan 20, 2023 6AM)

Little is known about the genetic determinants of medication use in preventing cardiometabolic diseases. Using the Finnish nationwide drug purchase registry with follow-up since 1995, we performed genome-wide association analyses of longitudinal patterns of medication use in hyperlipidemia, hypertension and type 2 diabetes in up to 193,933 individuals (55% women) in the FinnGen study. In meta-analyses of up to 567,671 individuals combining FinnGen with the Estonian Biobank and the UK Biobank, we discovered 333 independent loci (P?<?5?×?10–9) associated with medication use.

Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: International observational federated study based on electronic health records through the 4CE consortium
B Moal et al, PLOS ONE, Jan 4, 2023 (Posted: Jan 05, 2023 5AM)

Among the 75,377 hospitalized patients with positive SARS-CoV-2 PCR, 1001 young adults presented with ARDS (7.8% of young hospitalized adults). Their mortality rate at 90 days was 16.2% and they presented with a similar complication rate for infection than older adults with ARDS. Peptic ulcer disease, paralysis, obesity, congestive heart failure, valvular disease, diabetes, chronic pulmonary disease and liver disease were associated with a higher risk of ARDS. We described a high prevalence of obesity (53%), hypertension (38%- although not significantly associated with ARDS), and diabetes (32%).

Feasibility of Precision Medicine in Hypertension Management—Scope and Technological Aspects
P Nitzan et al, J Per Med, November 7, 2022 (Posted: Nov 07, 2022 9AM)

While the use of genomic and proteomic personal features for widespread precision hypertension management is not practical, other features, such as age, ethnicity, and cardiovascular diseases, have been utilized in guidelines for hypertension management. In precision medicine, more blood-pressure-related clinical and physiological characteristics can be utilized for the determination of the threshold of hypertension and optimal treatment. Several non-invasive and simple-to-use techniques for the measurement of hypertension-related physiological features are suggested for use in precision management of hypertension

Preeclampsia, Genomics and Public Health
E Dawson et al, CDC Blog Post, October 25, 2022 (Posted: Oct 25, 2022 10AM)

Preeclampsia is estimated to occur in 5 to 7 percent of all pregnancies and is one of the leading causes of maternal morbidity. Risk factors for preeclampsia include first pregnancy; history of preeclampsia; history of hypertension, chronic kidney disease, or both; history of thrombophilia (a condition that increases risk of blood clots); pregnancy from in vitro fertilization; family history of preeclampsia. A recent study identified a cell free RNA (cfRNA) signature that was promising in predicting pre-eclampsia several weeks before the onset of symptoms.

Fitbit step counts clarify the association between activity and chronic disease risk
Nature Medicine, October 11, 2022 (Posted: Oct 12, 2022 8AM)

Using electronic health records data from the All of Us Research Program, we show that higher daily step counts in data collected over several years of Fitbit fitness tracker use were associated with lower risk of common, chronic diseases, including diabetes, hypertension, gastroesophageal reflux disease, depression, obesity and sleep apnea.

Modeling global 80-80-80 blood pressure targets and cardiovascular outcomes
SJ Pickersgill et al, Nature Medicine, July 18, 2022 (Posted: Jul 19, 2022 7AM)

We developed a population CVD model using country-level evidence on CVD rates, blood pressure levels and hypertension intervention coverage. Under realistic implementation conditions, most countries could achieve 80-80-80 targets by 2040, reducing all-cause mortality by 4–7% (76–130 million deaths averted over 2022–2050) and slowing the rise in CVD expected from population growth and aging (110–200 million cases averted).

Incorporating family history of disease improves polygenic risk scores in diverse populations
MLA Hujeol et al, Cell Genomics, July 13, 2022 (Posted: Jul 14, 2022 7AM)

Polygenic risk scores (PRSs) derived from genotype data and family history (FH) of disease provide valuable information for predicting disease risk, but PRSs perform poorly when applied to diverse populations. Here, we explore methods for combining both types of information (PRS-FH) in UK Biobank data. We evaluated PRS, FH, and PRS-FH using liability-scale R2, primarily focusing on 3 well-powered diseases (type 2 diabetes, hypertension, and depression). PRS attained average prediction R2s of 5.8%, 4.0%, and 0.53% in non-British Europeans, South Asians, and Africans, confirming poor cross-population transferability. In contrast, PRS-FH attained average prediction R2s of 13%, 12%, and 10%, respectively, representing a large improvement in Europeans and an extremely large improvement in Africans. In conclusion, including family history improves the accuracy of polygenic risk scores, particularly in diverse populations.

Blood pressure measurement using only a smartphone
L Frey et al, NPJ Digital Medicine, July 6, 2022 (Posted: Jul 07, 2022 7AM)

We conducted a literature search on blood pressure measurement using only a smartphone, which has the potential to overcome current limitations and thus pave the way for long-term ambulatory blood pressure monitoring on a large scale. The methodologies applied for the evaluation of blood pressure measurement accuracy vary considerably among the analyzed articles. There is no consistency regarding the methods for blood pressure data collection and the reference blood pressure measurement and validation. Moreover, no established protocol is currently available for the validation of blood pressure measuring technologies using only a smartphone.

Clinical Characterization of Copy Number Variants Associated With Neurodevelopmental Disorders in a Large-scale Multiancestry Biobank.
Birnbaum Rebecca et al. JAMA psychiatry 2022 1 (3) 250-259 (Posted: Mar 03, 2022 8AM)

In this series of phenotypic association analyses including data from 24 877 individuals, the overall prevalence of NDD CNVs in the biobank was found to be 2.5%. NDD CNV carriers were enriched for congenital disorders and major depressive disorder, and the presence of NDD CNVs was found to be associated with several medical outcomes, including hypertension, obesity, and obesity-related phenotypes, specifically obstructive sleep apnea and increased body mass index.

Diagnostic accuracy of mercurial versus digital blood pressure measurement devices: a systematic review and meta-analysis
M Muniyandi et al, Scientific Reports, March 1, 2022 (Posted: Mar 02, 2022 7AM)

The digital blood pressure monitoring has a moderate level of accuracy and the device can correctly distinguish hypertension with a pooled estimate sensitivity of 65.7% and specificity of 95.9%. After removing one study, which had very low sensitivity and very high specificity, the pooled sensitivity estimate was 79%, and the specificity was 91%. The meta-analysis of DOR suggests that the digital blood pressure monitor had moderate accuracy with a mercury sphygmomanometer. This will provide the clinician and patients with accurate information on blood pressure with which diagnostic and treatment decisions could be made.

Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease.
Zheng Jie et al. International journal of epidemiology 2021 10 (Posted: Oct 24, 2021 6PM)

51, 672 CKD cases and 958 102 controls of European ancestry from CKDGen, UK Biobank and HUNT, and 13 093 CKD cases and 238 118 controls of East Asian ancestry from Biobank Japan, China Kadoorie Biobank and Japan-Kidney-Biobank/ToMMo were included. Eight risk factors showed reliable evidence of causal effects on CKD in Europeans, including genetically predicted body mass index (BMI), hypertension, systolic blood pressure, high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein(a), type 2 diabetes (T2D) and nephrolithiasis. In East Asians, BMI, T2D and nephrolithiasis showed evidence of causality on CKD.

Evidence Used to Update the List of Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19
CDC Science Brief, October 14, 2021 Brand (Posted: Oct 16, 2021 8AM)

Chronic lung disease (including bronchiectasis, bronchopulmonary dysplasia, interstitial lung disease, pulmonary hypertension, pulmonary embolism, tuberculosis) and chronic liver disease (including cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, and autoimmune hepatitis) were added September 2021 based on evidence published between December 1, 2019 and August 31, 2021 using the updated review methods outlined below. Mental health disorders (such as mood disorders including depression, and schizophrenia spectrum disorders) were added September 2021 based on evidence published between December 1, 2019 and August 31, 2021. No conditions were removed from the previous underlying medical conditions list.

Mobile health technology for diverse populations: challenges and opportunities
JA Diao et al, NPJ Digital Medicine, September 6, 2021 (Posted: Sep 06, 2021 7AM)

Nearly half of US adults have hypertension, and three in four cases are not well-controlled. Due to structural barriers, underserved communities face greater burdens of disease, less consistent management, and worse outcomes. Mobile technology presents an opportunity to reduce financial, geographic, and workforce barriers, but little data currently support its use in populations with digital disparities. A recent article systematically reviews the literature to quantify outcomes for these populations and provide a roadmap toward more inclusive mobile health strategies.

Mobile health strategies for blood pressure self-management in urban populations with digital barriers: systematic review and meta-analyses
EC Khoong et al, NPJ Digital Medicine, July 22, 2021 (Posted: Jul 23, 2021 7AM)

Mobile health (mHealth) technologies improve hypertension outcomes, but it is unknown if this benefit applies to all populations. This review aimed to describe the impact of mHealth interventions on blood pressure outcomes in populations with disparities in digital health use.

Familial hypercholesterolemia related admission for acute coronary syndrome in the United States: Incidence, predictors, and outcomes.
Kheiri Babikir et al. Journal of clinical lipidology 2021 (Posted: Jun 04, 2021 8AM)

Individuals with FH admitted for ACS were younger (median age 57 vs 69 y), had fewer comorbidities (hypertension 74.7% vs 79.6%; diabetes mellitus 30.5% vs 39.0%;p<0.01), were more likely to present with ST-elevation-myocardial infarction (32.8% vs 22.6%;p<0.01) and more likely to undergo multivessel percutaneous coronary intervention (11.4% vs 7.6%;p<0.01) than patients without FH. After propensity-score matching, FH patients more commonly experienced in-hospital VT arrest (11.8% vs 8.0%;p<0.01) and required more mechanical circulatory support (8.6% vs 3.3%; p<0.01). The 30-day readmission in those with FH was more frequently for cardiovascular disease (81.5% vs 46.5%; =p<0.01).

Central obesity, smoking habit and hypertension are associated with a blunted serological response to COVID-19 mRNA vaccine
M Watanabe et al, MERXIV, April 15, 2021 (Posted: Apr 16, 2021 7AM)

Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan
L Citterio et al, The Pharmacogenomics Journal, March 1, 2021 (Posted: Mar 02, 2021 8AM)

Risk factors for illness severity among pregnant women with confirmed SARS-CoV-2 infection - Surveillance for Emerging Threats to Mothers and Babies Network, 20 state, local, and territorial health departments, March 29, 2020 -January 8, 2021
RR Galang et al, MEDRXIV, March 1, 2021 (Posted: Mar 02, 2021 8AM)

Among 5,963 pregnant women with SARS-CoV-2 infection, moderate-to-severe or critical COVID-19 illness was associated with age 30-39 years, Black/Non-Hispanic race/ethnicity, healthcare occupation, pre-pregnancy obesity, chronic lung disease, chronic hypertension, cardiovascular disease, pregestational diabetes mellitus or gestational diabetes. Risk of moderate-to-severe or critical illness increased with the number of underlying medical or pregnancy-related conditions.

Non-communicable diseases pandemic and precision medicine: Is Africa ready?
T Chikowore et al, Ebiomedicine, February 2021 (Posted: Mar 01, 2021 8AM)

Africa has been lagging behind in genetic research, a key component of the precision medicine initiative. A number of genomic research initiatives which could lead to translational genomics are emerging on the African continent. This review evaluates the advances of genetic studies for cancer, hypertension, type 2 diabetes and body mass index (BMI) in Africa.

Polygenic Risk Scores Predict Hypertension Onset and Cardiovascular Risk.
Vaura Felix et al. Hypertension (Dallas, Tex. : 1979) 2021 HYPERTENSIONAHA12016471 (Posted: Feb 26, 2021 2PM)

American Heart Month 2021- Feeling the pressure? We can help.
CDC, February 2021 Brand (Posted: Feb 02, 2021 11AM)

February is American Heart Month, a time when all people can focus on their cardiovascular health. The CDC Division for Heart Disease and Stroke Prevention is shining a light on hypertension (high blood pressure), a leading risk factor for heart disease and stroke.

Genomics of hypertension: the road to precision medicine.
Padmanabhan Sandosh et al. Nature reviews. Cardiology 2020 Nov (Posted: Nov 28, 2020 0PM)

In this Review, we appraise the current knowledge of blood pressure genomics, explore the causal pathways for hypertension identified in Mendelian randomization studies and highlight the opportunities for drug repurposing and pharmacogenomics for the treatment of hypertension.

Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals
P Surendran et al, Nature Genetics, NOvember 23, 2020 (Posted: Nov 24, 2020 8AM)

Association of Genetic West African Ancestry, Blood Pressure Response to Therapy, and Cardiovascular Risk Among Self-Reported Black Individuals in the Systolic Blood Pressure Reduction Intervention Trial (SPRINT)
S Rao et al, JAMA Cardiology, November 12, 2020 (Posted: Nov 14, 2020 10AM)

Global West African ancestry proportion was not significantly associated with response to antihypertensive medication, blood pressure control, or kidney function changes over time. These findings highlight the greater importance of nonbiological risk factors—including socioeconomic status, environmental factors, educational attainment, behavioral characteristics in hypertension control and downstream adverse cardiovascular risk.

Disentangling Ancestry From Social Determinants of Health in Hypertension Disparities—An Important Step Forward
TM Powel-Wiley, JAMA Cardiology, November 13, 2020 (Posted: Nov 13, 2020 3PM)

We are having difficult but necessary conversations about racial/ethnic health disparities in cardiovascular (CV) medicine. Instead of an implied assumption that racial/ethnic disparities in CV disease (CVD) morbidity and mortality are driven by inherently biologic differences across racial/ethnic groups, we are beginning to acknowledge as a medical and research community that race is what it has always been: a social construct.

Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 131 US Veterans With SARS-CoV-2 Infection
GN Ioannou et al, JAMA Network Open, September 23, 2020 (Posted: Sep 23, 2020 1PM)

In this national cohort of VA patients, most SARS-CoV-2 deaths were associated with older age, male sex, and comorbidity burden. Many factors previously reported to be associated with mortality in smaller studies were not confirmed, such as obesity, Black race, Hispanic ethnicity, chronic obstructive pulmonary disease, hypertension, and smoking.

Regardless of Age, Obesity and Hypertension Increase Risks With COVID-19
MH Katz, JAMA Internal Medicine, September 9, 2020 (Posted: Sep 09, 2020 3PM)

Obesity and Hypertension in the Time of COVID-19
G Rodgers et al, JAMA September 9, 2020 (Posted: Sep 09, 2020 3PM)

The confluence of disturbing trends in obesity, hypertension, and COVID-19 within communities of color appears to reflect a complex interplay of contributing factors that are rooted in the social determinants of health and structural racism.

Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis
V Chidambaram et al, MEDRXIV, August 13, 2020 (Posted: Aug 13, 2020 7AM)

109 articles were included. The risks of mortality or severe diseases were higher in patients with increasing age, male gender, dyspnea, diabetes, hypertension, congestive heart failure, hilar lymphadenopathy, bilateral lung involvement and reticular pattern.

Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies
M Parohan et al MEDRXIV, June 4, 2020 (Posted: Jun 05, 2020 7AM)

14 studies with 29,909 COVID-19 infected patients and 1,445 cases of death were included in the current meta-analysis. Older age (=65 years old), male gender, hypertension, CVDs, diabetes, COPD and malignancies were associated with greater risk of death from COVID-19 infection.

Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19
A Ip et al, MEDRXIV, April 29, 2020 (Posted: Apr 29, 2020 8AM)

Nearly All Patients Hospitalized With Covid-19 Had Chronic Health Issues, Study Finds- Only 6 percent of patients at one New York area health system had no chronic conditions. Hypertension, obesity and diabetes were common.
RC Rabin, NY Times, April 23, 2020 (Posted: Apr 24, 2020 8AM)

Your Risk of Getting Sick From Covid-19 May Lie in Your Genes
Bloomberg News, April 16, 2020 (Posted: Apr 19, 2020 9AM)

We know that age and underlying health conditions, such as hypertension, play a large role in determining how people fare once they’ve contracted Covid-19. Studying the genetics of the virus and people who are more susceptible to SARS-CoV-2 could not only help identify and protect those more at risk but also help speed treatment and drug development.

Accuracy of Smartphone Camera Applications for Detecting Atrial Fibrillation- A Systematic Review and Meta-analysis
JW O'SUllivan et al, JAMA Network Open, April 3, 2020 (Posted: Apr 05, 2020 8AM)

In this meta-analysis of 10 primary diagnostic accuracy studies with 3852 participants, all applications that used photoplethysmography signals to diagnose AF had high sensitivity and specificity. The modeled positive predictive value for screening an asymptomatic population aged 65 years and older with a history of hypertension was approximately 20% to 40%.

Risk factors for severe corona virus disease 2019 (COVID-19) patients : a systematic review and meta analysis
L Xu et al, MEDRXIV, April 1, 2020 (Posted: Apr 02, 2020 10AM)

In this review and meta-analysis, we found that elderly male patients with a high body mass index, high breathing rate and a combination of underlying diseases (such as hypertension, diabetes, cardiovascular disease, and chronic obstructive pulmonary disease) were more likely to become critically ill.

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
Danser A H Jan et al. Hypertension (Dallas, Tex. : 1979) 2020 Mar HYPERTENSIONAHA12015082 (Posted: Mar 26, 2020 1PM)

In summary, based on the currently available evidence, treatment with renin-angiotensin system blockers should not be discontinued because of concerns with coronavirus infection.

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
Patel Ankit B et al. JAMA 2020 Mar (Posted: Mar 25, 2020 9AM)

There is insufficient clinical or scientific evidence to determine how to appropriately manage hypertension in the setting of COVID-19. Until more substantial data are available to guide decision-making one way or the other, physicians should be available to listen to patients’ concerns and provide reassuring advice about antihypertensive medications.

Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers
European Society for Cardiology, March 13, 2020 (Posted: Mar 15, 2020 0PM)

The Council on Hypertension strongly recommend that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest that treatment with ACEi or ARBs should be discontinued because of the Covid-19 infection.

Effect of Home Blood Pressure Monitoring via a Smartphone Hypertension Coaching Application or Tracking Application on Adults With Uncontrolled Hypertension- A Randomized Clinical Trial
SD Persell et al, JAMA Network Open, March 2, 2020 (Posted: Mar 03, 2020 8AM)

Does an artificial intelligence smartphone app improve blood pressure and hypertension-associated behaviors? In this randomized clinical trial of adults with uncontrolled hypertension, participants randomized to a smartphone coaching app did not have lower blood pressure at 6 months compared with those receiving a blood pressure tracking app.

Molecular genetic framework underlying pulmonary arterial hypertension.
Southgate Laura et al. Nature reviews. Cardiology 2019 Aug (Posted: Nov 06, 2019 9AM)

Precision medicine: The future of diagnostic approach to pulmonary hypertension?
Kedzierski Piotr et al. Anatolian journal of cardiology 2019 Sep (4) 168-171 (Posted: Nov 06, 2019 9AM)

Association of Daytime and Nighttime Blood Pressure With Cardiovascular Disease Events Among African American Individuals.
Yano Yuichiro et al. JAMA cardiology 2019 Aug (Posted: Aug 26, 2019 9AM)

In this cohort study of 1034 African American individuals, higher daytime and nighttime systolic blood pressures were associated with an increased risk for cardiovascular disease events independent of blood pressure levels measured in the clinic.

Gene and environmental interactions according to the components of lifestyle modifications in hypertension guidelines.
Kokubo Yoshihiro et al. Environmental health and preventive medicine 2019 Mar (1) 19 (Posted: Mar 14, 2019 9AM)

High Blood Pressure During Childhood and Adolescence
CDC, 2019 Brand (Posted: Mar 03, 2019 10AM)

Hypertension genetic risk score is associated with burden of coronary heart disease among patients referred for coronary angiography.
Lukács Krogager Maria et al. PloS one 2018 13(12) e0208645 (Posted: Jan 02, 2019 4PM)

Can You Inherit Pulmonary Hypertension? Here’s What You Should Know
Cleveland Clinic, December 10, 2018 (Posted: Dec 11, 2018 10AM)

Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits.
Evangelou Evangelos et al. Nature genetics 2018 Sep (Posted: Sep 19, 2018 11AM)

Hypertension genomics and cardiovascular prevention.
Ng Fu Liang et al. Annals of translational medicine 2018 Aug 6(15) 291 (Posted: Sep 19, 2018 9AM)

Genetics in pulmonary arterial hypertension in a large homogeneous Japanese population.
Gamou S et al. Clinical genetics 2018 Jul (1) 70-80 (Posted: Aug 08, 2018 11AM)

Recent advances in pulmonary arterial hypertension.
Wilkins Martin R et al. F1000Research 2018 (Posted: Aug 08, 2018 11AM)

Pulmonary Hypertension Fact Sheet
CDC Information, 2018 Brand (Posted: Aug 08, 2018 11AM)

Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment.
Eadon Michael T et al. Expert review of precision medicine and drug development 2018 3(1) 33-47 (Posted: Jun 20, 2018 9AM)

The Use of Precision Medicine to Manage Obstructive Sleep Apnea Treatment in Patients with Resistant Hypertension: Current Evidence and Future Directions.
Sapiña Esther et al. Current hypertension reports 2018 Jun 20(7) 60 (Posted: Jun 11, 2018 11AM)

Genetics of Resistant Hypertension: the Missing Heritability and Opportunities.
Teixeira Samantha K et al. Current hypertension reports 2018 May 20(6) 48 (Posted: May 23, 2018 9AM)

Omics of Blood Pressure and Hypertension
DK Arnett et al, Circulation Res, May 2018 (Posted: May 12, 2018 10AM)

Genetic factors contributing to hypertension in African-based populations: A systematic review and meta-analysis.
Yako Yandiswa Y et al. Journal of clinical hypertension (Greenwich, Conn.) 2018 Mar (Posted: Mar 11, 2018 1PM)

A systematic review of genetic mutations in pulmonary arterial hypertension.
Garcia-Rivas Gerardo et al. BMC medical genetics 2017 08 (1) 82 (Posted: Mar 07, 2018 9AM)

Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention.
Shilo Natalie R et al. Expert review of hematology 2017 10 (10) 875-890 (Posted: Mar 07, 2018 9AM)

Heritable pulmonary hypertension: from bench to bedside.
Girerd Barbara et al. European respiratory review : an official journal of the European Respiratory Society 2017 Sep (145) (Posted: Mar 07, 2018 9AM)

Precision medicine in pulmonary hypertension: Start with the end (point).
Mathai Stephen C et al. International journal of cardiology 2018 Apr 257339-340 (Posted: Mar 07, 2018 9AM)

Genetic Programming of Hypertension.
Ahn Sun-Young et al. Frontiers in pediatrics 2017 285 (Posted: Feb 13, 2018 3PM)

Genetic Predisposition to High Blood Pressure and Lifestyle Factors: Associations with Midlife Blood Pressure Levels and Cardiovascular Events.
Pazoki Raha et al. Circulation 2017 Dec (Posted: Feb 13, 2018 3PM)

Personalized medicine-a modern approach for the diagnosis and management of hypertension.
Savoia Carmine et al. Clinical science (London, England : 1979) 2017 Nov (22) 2671-2685 (Posted: Nov 20, 2017 2PM)

Recent development of risk-prediction models for incident hypertension: An updated systematic review.
Sun Dongdong et al. PloS one 2017 (10) e0187240 (Posted: Nov 20, 2017 2PM)

Family history of high blood pressure focuses trainer’s mission on heart health
American Heart Association News, May 31, 2017 (Posted: Jun 03, 2017 8PM)

Heritability and risks associated with early onset hypertension: multigenerational, prospective analysis in the Framingham Heart Study
TJ Niiranen et al, BMJ, May 12, 2017 (Posted: May 15, 2017 5PM)

A Review of the Genetics of Hypertension with a Focus on Gene-Environment Interactions.
Waken R J et al. Current hypertension reports 2017 Mar (3) 23 (Posted: May 12, 2017 8AM)

The evolving science of apolipoprotein-L1 and kidney disease.
Chen Teresa K et al. Current opinion in nephrology and hypertension 2016 May (3) 217-25 (Posted: Jan 18, 2017 8AM)

Under pressure — genetics of hypertension
L Koch, Nature Rev Genetics, Sept 26, 2016 (Posted: Sep 29, 2016 10PM)

Blood Pressure Control
CDC Vital Signs, September 13, 2016 Brand (Posted: Sep 14, 2016 11AM)

Undiagnosed Hypertension
Brand (Posted: Apr 07, 2016 0PM)

Information on Hypertension (High Blood Pressure)
About 1 of 3 U.S. adults?or about 70 million people?have high blood pressure. Only about half of these people have their high blood pressure under control Brand (Posted: Jan 19, 2016 2PM)

Genomics and Pharmacogenomics of Salt-sensitive Hypertension.
Armando Ines et al. Current hypertension reviews 2015 (1) 49-56 (Posted: Jan 08, 2016 9AM)

Genetics of Resistant Hypertension: a Novel Pharmacogenomics Phenotype.
El Rouby Nihal et al. Curr. Hypertens. Rep. 2015 Sep (9) 583 (Posted: Aug 24, 2015 11AM)

Pharmacogenomics of Hypertension and Heart Disease.
Arwood Meghan J et al. Curr. Hypertens. Rep. 2015 Sep (9) 586 (Posted: Aug 24, 2015 11AM)

Mechanisms of Salt-Sensitive Hypertension.
Luzardo Leonella et al. Curr Hypertens Rev 2015 (1) 14-21 (Posted: Jul 06, 2015 8AM)

Fetal programming and epigenetic mechanisms in arterial hypertension.
Scherrer Urs et al. Curr. Opin. Cardiol. 2015 Jul (4) 393-7 (Posted: Jul 06, 2015 8AM)

APOL1 genetic variants, chronic kidney diseases and hypertension in mixed ancestry South Africans.
Matsha Tandi E et al. BMC Genet. 2015 (1) 69 (Posted: Jun 30, 2015 3PM)

Mutation of SH2B3 (LNK), a Genome-Wide Association Study Candidate for Hypertension, Attenuates Dahl Salt-Sensitive Hypertension via Inflammatory Modulation.
Rudemiller Nathan P et al. Hypertension 2015 May (5) 1111-7 (Posted: May 06, 2015 0PM)

A meta-analysis of gene expression signatures of blood pressure and hypertension.
Huan Tianxiao et al. PLoS Genet. 2015 Mar (3) e1005035 (Posted: May 06, 2015 0PM)

Association of genetic variants with hypertension in a longitudinal population-based genetic epidemiological study.
Yamada Yoshiji et al. Int. J. Mol. Med. 2015 May (5) 1189-98 (Posted: May 06, 2015 0PM)

The ACE2/Apelin Signaling, MicroRNAs, and Hypertension.
Chen Lai-Jiang et al. Int J Hypertens 2015 896861 (Posted: May 06, 2015 0PM)

Genomic Research in Postmenopausal Hypertension.
Thomopoulos Costas et al. J Clin Hypertens (Greenwich) 2015 Mar 31. (Posted: May 06, 2015 0PM)

Non-coding RNAs and Hypertension-Unveiling Unexpected Mechanisms of Hypertension by the Dark Matter of the Genome.
Murakami Kazuo et al. Curr Hypertens Rev 2015 Mar 31. (Posted: May 06, 2015 0PM)

Association of adiponectin with type 2 diabetes and hypertension in African American men and women: the Jackson Heart Study.
Davis Sharon K et al. BMC Cardiovasc Disord 2015 (1) 13 (Posted: May 06, 2015 0PM)

Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism.
Scholl Ute I et al. Elife 2015 (Posted: May 06, 2015 0PM)

The importance of G protein-coupled receptor kinase 4 (GRK4) in pathogenesis of salt sensitivity, salt sensitive hypertension and response to antihypertensive treatment.
Rayner Brian et al. Int J Mol Sci 2015 (3) 5741-9 (Posted: May 06, 2015 0PM)

Genetic and molecular aspects of hypertension.
Padmanabhan Sandosh et al. Circ. Res. 2015 Mar 13. (6) 937-59 (Posted: May 06, 2015 0PM)

Efficacy of Folic Acid Therapy in Primary Prevention of Stroke Among Adults With Hypertension in ChinaThe CSPPT Randomized Clinical Trial
Y Huo et al. JAMA, March 12, 2015 (Posted: Mar 16, 2015 9AM)

more


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP